Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.
about
Frequency of human immunodeficiency virus type-2 in hiv infected patients in Maputo City, MozambiqueSVARAP and aSVARAP: simple tools for quantitative analysis of nucleotide and amino acid variability and primer selection for clinical microbiology.Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg databasePolymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.Polymorphisms of HIV-2 integrase and selection of resistance to raltegravirAntiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsCell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patientsHIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsEmergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West AfricaComplex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.Antiretroviral drug resistance in human immunodeficiency virus type 2.Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System.Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene.HIV-2 Protease resistance defined in yeast cells.High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
P2860
Q30406079-96B5831A-8A91-49A5-A715-B2CF20B79980Q30810347-82D45C24-C8C8-41B1-B617-FBDC4FDB9059Q33321434-35ED8D80-01CB-4986-B952-A7F05055CFEBQ33593237-1B3C0442-518B-40C7-BD4A-C35778B82705Q34426605-C221498C-7B62-4BCC-9E94-948B7ED404F5Q34730950-65C049E7-3C2C-44C1-BB88-6FB64FC78920Q34742090-1A08F241-8C3D-4410-A285-880AB8E52066Q35134947-21258426-E30B-4C4C-B054-A4BCD61BE899Q35636029-6B64336C-6336-4242-904F-1FD73FA6458FQ36897863-301021FB-E1FB-48FE-9824-187FF9985B3CQ37026564-4A3CE904-8423-4E99-9677-F018C893542EQ37083896-38D8A220-3135-40FB-8776-F634145172A9Q37130458-3A3C7ED7-AA01-44E7-B390-3E74271C9946Q37256366-274D7783-528A-4AFF-9D5E-1C60A8F7E3ACQ37307096-8EB0643E-3F3E-47EA-8055-292A94D59A8DQ37496287-5F9363C3-97CF-40A2-A338-7851895CAFC0Q38814591-C46261AD-018F-4BD6-BB15-8F8789699D21Q40353488-05BDED7A-F281-47C8-A49C-DEF760B9C27CQ41761525-BD5777F2-2C8F-4CD3-8094-D97ED470F6F9Q43249256-E47130E6-BDD6-4433-AB05-5DE3CB769E12Q45032977-E30795DD-8A45-4B28-B90F-CFB60BD19DACQ46933139-A9EAE2F2-D6D0-420B-9A8F-A719B80DC12A
P2860
Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Polymorphism and drug-selected ...... nts living in Southern France.
@ast
Polymorphism and drug-selected ...... nts living in Southern France.
@en
type
label
Polymorphism and drug-selected ...... nts living in Southern France.
@ast
Polymorphism and drug-selected ...... nts living in Southern France.
@en
prefLabel
Polymorphism and drug-selected ...... nts living in Southern France.
@ast
Polymorphism and drug-selected ...... nts living in Southern France.
@en
P2093
P2860
P1476
Polymorphism and drug-selected ...... nts living in Southern France.
@en
P2093
D Lozachmeur
J A Gastaut
P2860
P304
P356
10.1128/JCM.42.2.570-577.2004
P407
P577
2004-02-01T00:00:00Z